References
- Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmaco-economics 2005;23:243–57
- Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000;3:243–52
- Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum 1995;38:1351–62
- Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42:588–96
- Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996;44:47–51
- Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004;43(Suppl 3): iii,17–23
- Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 2005;72:46–7
- Lyseng-Williamson KA, Plosker GL. Etanercept: a pharmaco-economic review of its use in rheumatoid arthritis. Pharmaco-economics 2004;22:1071–95
- Lyseng-Williamson KA, Foster RH. Infliximab: a pharmaco-economic review of its use in rheumatoid arthritis. Pharmaco-economics 2004;22:107–32
- Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995–1002
- Doan QV, Chiou CF, Dubois RW. Review of eight pharmaco-economic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006;12:555–69
- Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
- Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383–93
- Weycker D, Yu EB, Woolley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or = 65 years with rheumatoid arthritis. Clin Ther 2005;27:646–56
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: 373–83
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613–19
- Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika 2000;87:706–10
- D’Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med 1998:17:2265–81